Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 6, 2011

166_ip_2011-05-06_f83dcd38-1bd8-4ff9-8f91-25df9db53004.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Analyst Conference Call – Q1/11 Results

May 4, 2011

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Fresenius Group: Excellent Start into 2011

S
l
a
e
s		 E
B
I
T		 1
i
N
t
e
n
c
o
m
e
Q
/
1
1
1		 €
3
9
6
2
m
,		 €
5
7
5
m		 €
0
1
7
m
h
G
t
t
t
t
o
a
c
o
n
s
a
n
r
w
t
c
e
n
c
a
e
s
u
r
r
y
r		 7
%		 3
1
%		 3
9
%
G
h
l
t
t
t
o
r
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 9
%		 1
5
%		 4
3
%

1Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Financial Results by Business Segment

/
Q
1
1
1		 i
F
r
e
s
e
n
u
s
d
i
l
M
C
e
c
a
a
r
e		 i
F
r
e
s
e
n
u
s
b
i
K
a		 i
F
r
e
s
e
n
u
s
l
i
H
e
o
s		 i
F
r
e
s
e
n
u
s
d
V
a
m
e
S
l
a
e
s
G
h
t
o
r
w		 \$
U
S
3
0
3
6
m
,
%
5		 €
9
6
0
m
2
0
%		 €
6
8
4
m
%
7		 €
0
1
4
m
0
%
1
-
E
B
I
T
h
G
t
o
r
w		 \$
U
S
4
4
5
m
5
%		 €
1
9
7
m
3
6
%		 €
8
5
m
2
%
1		 €
5
m
2
9
%
-

Fresenius Kabi: Update Q1/11

  • Excellent start into the year
  • -Record organic sales growth of 16%
  • 20.5% EBIT margin
  • 39% organic sales growth in North America
  • Drug-shortage-related sales expanded in March 2010
    • 2010/11 product launches, e.g. Gemcitabine, Aztreonam, Topotecan
  • 10% organic sales growth outside North America
  • -Continued strong emerging markets growth
  • Europe performing well at 8%

Fresenius Helios: Update Q1/11

    • 5% organic sales growth at upper end of expectations; strong EBIT margin of 9.0%
    • YTD 2011 slight revival of hospital privatization activity; ~10 transactions pending/concluded
    • 264-bed Rottweil hospital (South/West) bid accepted, closing expected for Q3 2011
    • Collective bargaining agreements for doctors/nurses successfully concluded, average pay rise of 2-3% p.a. through December 2012; in line with budget assumptions

Fresenius Vamed: Update Q1/11

  • Sales and EBIT development fully in line with expectations
  • Order backlog at all-time high (€842 million)
  • Order intake (€127 million)
  • Turnkey construction project in the Ukraine (€67 million)
  • Medical equipment contract from the National Cancer Institute of Malaysia (€29 million)

Fresenius Group: Net Income Growth excl. FMC Outpaced Valuation

Group Financials Q1/11 − Outlook 2011

Fresenius Group: Profit and Loss Statement

€
m		 /
Q
1
1
1		 /
Q
1
1
0		 h
/
G
Q
1
1
1
Y
t
r
o
w
o
l
t
a
c
u
a
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s
S
l
e
a
s		 3
9
6
2
,		 3
6
3
4
,		 9
%		 %
7
E
B
I
T		 5
7
5		 5
0
1		 1
5
%		 1
3
%
N
i
t
t
t
e
n
e
r
e
s		 3
1
5
-		 3
1
4
-		 6
%		 %
7
I
t
n
c
o
m
e
a
e
s
x		 1
3
5
-		 1
1
9
-		 1
3
%
-		 1
3
%
-
1
N
i
t
e
n
c
o
m
e		 0
1
7		 9
1
1		 3
%
4		 3
9
%

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Kabi: Excellent EBIT Growth

€
m		 /
Q
1
1
1		 /
Q
1
1
0		 h
G
t
r
o
w
E
u
r
o
p
e
i
M
a
r
g
n		 9
5
2
2
%
1.		 8
6
2
0
%
1.		 0
%
1
h
N
A
i
t
o
r
m
e
r
c
a
M
i
a
r
g
n		 9
6
3
7.
8
%		 4
7
2
6.
3
%		 1
0
4
%
f
/
/
f
A
i
P
i
i
L
i
A
i
A
i
t
s
a
a
c
c
a
n
m
e
c
a
c
a
r
r
-
M
i
a
r
g
n		 4
2
6.
3
%
1		 3
5
6.
%
1
5		 2
0
%
C
d
C
&
R
D
t
t
o
p
o
a
e
a
n
o
p
o
a
e
r
r
r
r		 3
6
-		 2
3
-		 %
5
7
-
l
T
E
B
I
T
t
o
a		 9
1
7		 1
4
5		 3
6
%
M
i
a
r
g
n		 2
0
5
%		 1
8
1
%

Fresenius Helios: Excellent Sales and EBIT Growth

€
m		 /
Q
1
1
1		 /
Q
1
1
0		 h
G
t
r
o
w
l
l
T
t
o
a
s
a
e
s		 6
4
8		 6
0
8		 %
7
E
B
I
T
b
l
h
d
l
f
l
i
i
i
i
E
t
t
s
a
s
e
c
n
c
p
o
o
o
r
M
i
a
g
n
r		 8
5
9
%
1		 5
2
8.
6
%		 1
2
%
/
A
i
i
i
D
i
i
t
t
t
c
q
s
o
n
s
e
s
e
s
u
v
u
r
(
l
d
/
d
l
d
)
i
i
i
i
1
t
t
<
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
y
r		 0 0
l
T
E
B
I
T
t
o
a		 5
8		 5
2		 1
2
%
i
M
a
g
n
r		 9
0
%		 8
6
%

Fresenius Vamed: Sales and EBIT Fully in Line with Expectations

€
m		 /
Q
1
1
1		 /
Q
1
1
0		 h
G
t
r
o
w
b
P
j
i
t
r
o
e
c
u
s
n
e
s
s
b
S
i
i
e
c
e
s
n
e
s
s
r
v
u		 8
4
5
6		 0
2
1
5
4		 8
%
1
-
4
%
l
l
T
t
o
a
s
a
e
s		 0
1
4		 6
1
5		 0
%
1
-
l
T
E
B
I
T
t
o
a
M
i
a
r
g
n		 5
3
6
%		 7
4
5
%		 2
9
%
-
1
d
i
k
O
t
r
e
r
n
a
e
1
d
b
k
l
O
r
e
r
a
c
o
g		 2
1
7
8
2
4		 2
6
0
2
8
0
1		 %
5
1
-
%
5

Cash Flow Development

€
m		 O
p
e
r
a		 i
(
)
h
C
F
C
F
C
t
t
n
g
a
p
e
x
n
e
r
e
e
a
s		 1
l
F
o
w
Q
1
/
1
1		 L
T
M
M
i
a
r
g
n		 Q
1
/
1
1		 L
T
M
M
i
a
r
g
n		 Q
1
/
1
1		 L
T
M
M
i
a
r
g
n
6
7		 1
4
6
%		 (
)
4
5		 (
)
4
7
%		 2
2		 9
9
%
6
8		 3
%
1
4		 (
)
1
7		 (
6
%
)
1		 5
1		 3
3
%
7
2
6		 2
3
%
-		 (
)
1		 (
)
1
3
%		 2
5		 3
6
%
-
/
Co
te
rp
or
a
O
he
t
r		 1
1
-		 /
n
a		 (
)
1		 /
n
a		 2
1
-		 /
n
a
l.
F
M
C
ex
c		 1
5
0		 2
1
2
8
%		 (
)
6
4		 (
)
5
0
%		 8
6		 2
7
8
%
G
ro
up		 2
8
7		 0
%
1
7		 (
)
1
4
7		 (
6
%
)
4		 3
1
1		 6
%
1

Margin = in % of sales

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 9.9% excluding €67 million of Capex commitments from acquisitions

Fresenius Group: Debt and Interest Ratios

Debt excludes Mandatory Exchangeable Bonds

Fresenius Group: 2011 Outlook Raised or Fully Confirmed

i
P
r
e
v
o
u
s		 N
e
w
i
F
e
s
e
n
s
r
u
b
i
K
a		 l
h
S
t
a
e
s
g
o
r
w
E
B
I
T
i
m
a
r
g
n		 5
%
i
o
g
a
n
c
r
~
9
0
%
1
>		 5
%
i
>
o
g
a
n
c
r
9
2
0
%
1
–
i
F
e
s
e
n
s
r
u
l
i
H
e
o
s		 l
h
S
t
a
e
s
g
o
r
w
E
B
I
T		 3
5
%
i
o
g
a
n
c
r
–
€
2
0
2
6
0
5
m
–		 h
l
f
f
U
p
p
e
r
a
o
r
a
n
g
e
i
F
e
s
e
n
s
r
u
d
V
a
m
e		 l
h
S
t
a
e
s
g
o
r
w
h
E
B
I
T
t
g
r
o
w		 5
1
0
%
–
0
5
1
%
–
i
F
e
s
e
n
s
r
u
i
h
B
t
o
e
c		 E
B
I
T		 €
3
0
m
~
-

Fresenius Group: 2011 Outlook Raised or Fully Confirmed

i
P
r
e
v
o
u
s		 N
e
w
h
R
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 7
%
 7
8
%
–
1
h
N
i
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
e
n
c
u
r
r
y		 8
1
2
%
–		 1
2
1
6
%
–
C
a
p
e
x		 f
l
%
G
5
o
o
p
s
a
e
s
r
u
~

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Attachments

Special items

    • Other financial result:
    • CVR (Contingent Value Right): The trading price of the CVR on the B/S date is considered as fair redemption value. Changes of this value are recognized in the P&L. Valuation changes will lead to quarterly gains or expenses until maturity.

Calculation as of March 31, 2011: between trading price of US\$0.04 at December 31, 2010 and value zero at March 31, 2011 multiplied by 163.3 million CVRs = US\$6.7 million = €4.9 million.

On March 4, 2011, the CVRs have been delisted from the NASDAQ and the NASDAQ suspended trading in the CVRs effective the close of trading on that day.

MEB (Mandatory Exchangeable Bond): Mark-to-market accounting based on the Black-Scholes valuation model reflecting FMC's share price. Any change in fair value is recognized in the P&L. Valuation changes will lead to gains or expenses until maturity. Maturity date will be August 14, 2011.

Fresenius Group:

Overview – Calculation of Noncontrolling Interest

€
m		 /
Q
1
1
1		 /
F
Y
1
0
b
f
d
l
l
E
i
i
i
t
t
t
t
n
n
g
e
o
e
n
n
o
n
o
n
o
n
g
n
e
e
a
r
s
r
a
x
a
c
r
r
s		 3
8
7		 8
6
1
7
,
T
a
e
s
x		 1
1
5
-		 5
8
1
-
l
l
h
f
N
i
i
t
t
t,
t
o
n
c
o
n
r
o
n
g
n
e
r
e
s
e
r
e
o		 1
3
5
-		 5
8
3
-
d
l
F
i
M
i
C
i
t
t
r
e
s
e
n
u
s
e
c
a
a
r
e
n
e
n
c
o
m
e
n
o
b
b
l
(
)
i
F
i
6
5
%
t
t
t
t
a
a
e
o
e
s
e
n
s
r
u
r
u
~		 1
0
4
-		 4
7
6
-
l
l
h
l
d
d
l
N
i
i
i
F
i
M
i
C
t
t
t
o
n
c
o
n
o
n
g
n
e
e
s
o
e
s
n
e
s
e
n
s
e
c
a
a
e
r
r
r
r
u
r
\$
\$
(
F
Y
/
2
0
1
0
U
S
8
7
Q
1
/
2
0
1
1
U
S
2
8
d
i
m
m
a
o
n
g
:
:
c
c
r
,
d
l
C
's
l
S
)
t
F
i
M
i
F
i
i
t
t
t
o
r
e
s
e
n
u
s
e
c
a
a
r
e
n
a
n
c
a
a
e
m
e
n
s		 2
1
-		 6
6
-
l
l
h
l
d
b
N
i
i
i
F
i
K
i
t
t
t
o
n
c
o
n
o
n
g
n
e
e
s
o
e
s
n
e
s
e
n
s
a
r
r
r
r
u
(
€
),
l
(
€
)
d
d
5
F
i
H
i
4
t
m
r
e
s
e
n
u
s
e
o
s
m
a
n
u
e
o
-
-
d
's
l
h
(
)
F
i
V
2
3
%
i
€
1
t
e
s
e
n
s
a
m
e
e
e
n
a
o
n
e
s
p
m
r
u
x
r
w
r
-		 1
0
-		 4
1
-
b
b
l
S
&
C
G
N
i
i
F
i
E
K
A
t
t
t
t
t
e
n
o
m
e
a
a
e
o
e
s
e
n
s
o
a
c
r
u
r
u		 2
8
1		 6
2
2

Fresenius Group: Cash Flow

€
m		 /
Q
1
1
1		 L
T
M
i
M
a
r
g
n		 /
Q
1
1
0		 L
T
M
i
M
a
r
g
n		 h
G
t
r
o
w
Y
Y
o
i
h
l
O
C
F
t
p
e
r
a
n
g
a
s
o
w		 2
7
8		 1
0
7
%		 4
3
8		 1
2
5
%		 3
7
%
-
C
(
)
t
a
p
e
x
n
e		 1
4
7
-		 6
%
4		 3
0
1
-		 %
4
5		 3
%
1
-
C
h
l
F
F
e
e
a
o
r
s
w
f
(
b
i
i
i
d
d
i
i
d
d
)
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 3
1
1		 6
%
1		 3
0
8		 8
%
1		 %
5
7
-
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 2
4
9
-		 6
6
-
d
d
D
i
i
v
e
n
s		 1
5
-		 2
4
-		 3
8
%
C
h
l
F
F
e
e
a
o
r
s
w
(
f
i
i
i
d
d
i
i
d
d
)
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 3
3
1
-		 - 2
8
1		 6
%
4		 6
%
1
1
-

Cash Flow Development LTM

€
m		 O
p
e
r
a		 i
C
F
t
n
g		 C
a
p
e		 (
)
t
x
n
e		 1
h
l
F
C
F
r
e
e
a
s
o
w
Q
/
L
T
M
1
1
1		 i
L
T
M
M
a
r
g
n		 Q
/
L
T
M
1
1
1		 i
L
T
M
M
a
r
g
n		 Q
/
L
T
M
1
1
1		 i
L
T
M
M
a
r
g
n
5
6
0		 1
4
6
%		 (
)
1
7
9		 (
)
4
7
%		 3
8
1		 9
9
%
3
3
4		 3
%
1
4		 (
6
)
1
5		 (
6
%
)
1		 8
1
7		 3
3
%
7
1
6
-		 2
3
%
-		 (
)
9		 (
)
1
3
%		 2
5
-		 3
6
%
-
Co
/
te
rp
or
a
he
O
t
r		 4
4
-		 /
n
a		 (
)
1
1		 /
n
a		 5
5
-		 /
n
a
l.
F
M
C
ex
c		 8
4
3		 2
1
2
8
%		 (
)
3
5
5		 (
)
5
0
%		 4
8
8		 2
7
8
%
G
ro
up		 1
7
5
1
,		 0
%
1
7		 (
0
)
7
5		 (
6
%
)
4		 0
0
1
1
,		 6
%
1

Margin = in % of sales

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 9.9% excluding €67 million of Capex commitments from acquisitions

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
1
1
1		 Q
/
0
1
1		 O
i
g
a
n
c
r
G
h
t
r
o
w
f
h
I
i
T
n
s
o
n
e
a
p
u
r
y		 2
2
0		 1
9
6		 6
%
I.
V
D
g
s
r
u		 3
5
5		 2
5
5		 3
7
%
l
l
C
i
i
N
i
i
t
t
n
c
a
u
r
o
n		 2
7
0		 2
4
5		 7
%
d
l
/
M
i
D
i
e
c
a
e
v
c
e
s
f
h
l
T
i
T
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 1
1
5		 0
1
4		 8
%
l
l
T
t
o
a
s
a
e
s		 9
6
0		 8
0
0		 6
%
1

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
1
1
1		 Q
/
0
1
1		 O
i
a
r
g
n
c
h
G
t
r
o
w
E
o
p
e
u
r		 9
4
4		 0
9
4		 8
%
h
N
A
i
t
o
r
m
e
r
c
a		 2
5
4		 1
7
9		 3
9
%
f
A
i
P
i
i
s
a
a
c
c
-		 1
5
6		 1
2
8		 1
6
%
/
f
i
i
i
L
t
A
A
a
n
m
e
c
a
c
a
r
r		 0
1
1		 8
4		 3
%
1
l
l
T
t
o
a
s
a
e
s		 9
6
0		 8
0
0		 1
6
%

Fresenius Helios: Strong Organic Sales Growth

€
m		 /
Q
1
1
1		 /
Q
1
1
0		 h
G
t
r
o
w
b
l
h
d
l
f
l
i
i
i
i
E
t
t
s
a
s
e
c
n
c
p
o
o
o
r		 6
3
9		 8
6
0		 5
%
A
i
i
i
t
q
o
n
(
l
d
)
c
u
s
s
i
i
1
t
<
c
o
n
s
o
a
o
n
y
r		 9
i
i
D
t
t
e
s
e
s
(
d
l
d
)
v
u
r
i
t
i
1
<
e
c
o
n
s
o
a
o
n
y
r		 0
l
l
T
t
o
a
s
a
e
s		 6
4
8		 6
0
8		 7
%

Fresenius Helios: Performance Indicators

/
Q
1
1
1		 /
Q
1
1
0		 h
C
a
n
g
e
1
f
h
l
N
i
t
o
o
o
s
p
a
s
l
A
t
i
i
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
3
3
4
2
0		 6
2
2
4
2
0		 2
%
2
%
0
%
1
f
b
d
N
o
o
e
s
l
i
i
A
t
c
u
e
c
a
r
e
c
n
c
s
-
l
P
t-
t
i
i
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 8
8
1
5
4
,
3
8
1
5,
7
3,
6
4
7		 8
6
1
5
4
,
0
9
1
5,
7
3,
6
4
7		 2
%
2
%
0
%
2
d
i
i
A
m
s
s
o
n
s
A
(
i
i
)
t
t
t
c
u
e
c
a
r
e
n
p
a
e
n
-		 1
6
0,
9
4
7		 1
5
2,
7
3
0		 5
%
2
O
c
c
p
a
n
c
u
y
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 7
8
%		 8
0
%
2
l
h
f
(
d
)
A
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
e
c
a
e
u
r
-
P
t-
t
o
s
a
c
e
c
a
e
u
r
-		 6.
6
2
9
8		 6.
9
3
0.
1

Dec 31, 2010

2Clinics in Germany

Fresenius Helios: Sales Influence Hospital Acquisitions

i
i
i
A
t
c
q
s
o
n
s
u		 l
i
d
l
A
n
n
a
e
s
a
e
s
u
z
l
l
d
H
i
H
t
t
t
o
s
p
a
e
m
s
e		 €
3
2
m
~		 l
d
d
f
i
J
1
2
0
1
1
t
c
o
n
s
o
a
e
a
s
o
a
n
,

Divestitures

none

Fresenius Group: Key Figures According to IFRS

€
m		 Q
/
1
1
1
U
S
G
A
A
P		 Q
/
1
1
1
I
F
R
S
l
S
a
e
s		 3
9
6
2
,		 3
9
6
2
,
E
B
I
T		 5
7
5		 8
5
7
N
i
t
t
t
e
n
e
e
s
r		 1
3
5
-		 1
3
5
-
1
N
i
t
e
n
c
o
m
e		 2
8
1		 9
1
2
2
i
N
t
e
n
c
o
m
e		 1
0
7		 1
1
7
h
f
l
O
i
C
t
p
e
r
a
n
g
a
s
o
w		 8
2
7		 8
2
0
l
h
l
B
t
t
t
a
a
n
c
e
s
e
e
o
a		 2
3
5
7
2
,		 2
3
7
4
3
,

1Net income attributable to Fresenius SE & Co. KGaA

2Net income attributable to Fresenius SE & Co. KGaA before special items due to MEB and CVR accounting

Financial Calendar

  • 13.05.2011 Annual General Meeting, Frankfurt/Main
  • 16.05.2011 Payment of dividend1
  • 02.08.2011 Report on 1st half 2011
  • 02.11.2011 Report on 1st 3rd quarter 2011

Contact

  • Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA
  • Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

1Subject to the prior approval by the Annual General Meeting

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.